Mobile

A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005154-57

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the long-term efficacy of canakinumab with respect to the maintenance of treatment response in CAPS patients who completed the CACZ885D2307 study

Critère d'inclusion

  • Cryopyrin Associated Periodic Syndromes (CAPS)

Liens